502533464 10/15/2013

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2578794

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	07/12/2013

CONVEYING PARTY DATA

Name	Execution Date
MSH PHARMA, INC.	07/12/2013

RECEIVING PARTY DATA

Name:	MSH BIOPHARMA, INC.
Street Address:	5050 SPRING VALLEY ROAD
City:	DALLAS
State/Country:	TEXAS
Postal Code:	75244

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	6894028

CORRESPONDENCE DATA

Fax Number:

Email: dwilson@wpparalegal.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: MSH BIOPHARMA, INC. Address Line 1: 5050 SPRING VALLEY ROAD Address Line 4: DALLAS, TEXAS 75244

ATTORNEY DOCKET NUMBER:	MSH-6894028
NAME OF SUBMITTER:	DENISE M. WILSON
Signature:	/Denise M. Wilson/
Date:	10/15/2013

PATENT

REEL: 031411 FRAME: 0365

502533464



STATE OF NEVADA

ROSS MILLER Secretary of State



SCOTT W. ANDERSON

Deputy Secretary

for Commercial Recordings

Certified Copy

August 2, 2013

Job Number: C20130802-0930 **Reference Number:** 00003990739-20

Expedite:

Through Date:

The undersigned filing officer hereby certifies that the attached copies are true and exact copies of all requested statements and related subsequent documentation filed with the Secretary of State's Office, Commercial Recordings Division listed on the attached report.

Document Number(s)DescriptionNumber of Pages20130477531-03Merge In11 Pages/1 Copies

Certified By: F Lincoln

Certificate Number: C20130802-0930

You may verify this certificate online at http://www.nvsos.gov/

Respectfully,

ROSS MILLER Secretary of State

Commercial Recording Division

202 N. Carson Street Carson City, Nevada 89701-4069 Telephone (775) 684-5708 Fax (775) 684-7138





ROSS MILLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4520 (775) 684-5708

Website: www.nvsos.gov

Articles of Merger (PURSUANT TO NRS 92A.200)

Page 1

Filed in the office of Ross Miller Secretary of State

State of Nevada

Document Number

20130477531-03

Filing Date and Time

07/18/2013 9:15 AM

Entity Number

E0305242013-5

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

Articles of Merger (Pursuant to NRS Chapter 92A)

	for each additional entity from article one.
MSH Pharma, Inc.	
Name of merging entity	
California	Corporation
Jurisdiction	Entity type *
Name of merging entity	
Jurisdiction	Entity type *
Name of merging entity	
Jurisdiction	Entity type *
Name of merging entity	
Jurisdiction	Entity type *
and,	
MSH BioPharma, Inc.	
Name of surviving entity	
Nevada	Corporation
Jurisdiction	Entity type *

* Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

Filing Fee: \$350.00

This form must be accompanied by appropriate fees.

Nevada Secretary of State 92A Merger Page 1 Revised: 8-31-11



Articles of Merger (PURSUANT TO NRS 92A.200)

Page 2

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

2)		ress where copies of process may be sent by the Secretary of State of ign entity is the survivor in the merger - NRS 92A.190):
	Attn:	
	c/o:	
3)	Choose one:	
	The unders (NRS 92A.2	igned declares that a plan of merger has been adopted by each constituent entity 00).
	The unders entity (NRS	igned declares that a plan of merger has been adopted by the parent domestic 92A.180).
4)	Owner's approval	(NRS 92A.200) (options a, b or c must be used, as applicable, for each entity):
	If there are containing article four.	more than four merging entities, check box and attach an 8 1/2" x 11" blank sheet the required information for each additional entity from the appropriate section of
	(a) Owner's appro	val was not required from
	Name of mer	ging entity, if applicable
	Name of mer	ging entity, if applicable
	Name of mer	ging entity, if applicable
	Name of mer	ging entity, if applicable
	and, or;	
	Name of surv	riving entity, if applicable

This form must be accompanied by appropriate fees.

Nevada Secretary of State 92A Merger Page 2 Revised: 8-31-11



(b) The plan was approved by the required consent of the owners of *:

Articles of Merger (PURSUANT TO NRS 92A.200)

(PURSUANT TO NRS 92A.200)
Page 3

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

MSH Pharma, Inc.	
Name of merging entity, if applicable	
Name of merging entity, if applicable	
Name of merging entity, if applicable	
Name of merging entity, if applicable	
and, or;	
MSH BioPharma, Inc.	
Name of surviving entity, if applicable	

This form must be accompanied by appropriate fees.

Nevada Secretary of State 92A Merger Page 3 Revised: 8-31-11

^{*} Unless otherwise provided in the certificate of trust or governing instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.



Articles of Merger (PURSUANT TO NRS 92A.200)

Page 4

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

(c) Approval of plan of merger for Nevada non-profit corporation (NRS 92A.160):

The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.

Name of merging entity, if applicable	
Name of merging entity, if applicable	
Name of merging entity, if applicable	
Name of merging entity, if applicable	
and, or;	
Name of surviving entity, if applicable	

This form must be accompanied by appropriate fees.

Nevada Secretary of State 92A Merger Page 4 Revised: 8-31-11



Articles of Merger (PURSUANT TO NRS 92A.200)

(PURSUANT TO NRS 92A.200)
Page 5

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

6) Location of Plan	of Merger (check a or	r b):		
		~,.		
(a) The en	tire plan of merger is a	ttached;		
or,				
(b) The en	tire plan of merger is on	file at the registered office	ce of the surviving co	orporation, limited
business o	f the surviving entity (N	ne records office address RS 92A.200).	if a limited partners!	nip, or other plac
7) Effective date and	time of filing: (option	al) (must not be later th	an 90 days after th	e certificate is f
	Date:	Time:		7
	Duto.	J 11110-1		

"Restated" or "Amended and Restated," accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent - Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the

This form must be accompanied by appropriate fees.

surviving entity except that the name of the surviving entity may be changed.

Nevada Secretary of State 92A Merger Page 5 Revised: 8-31-11



Articles of Merger (PURSUANT TO NRS 92A.200)

Page 6

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

Name of merging entity		
Signature Name of merging entity	Title	Date
X Signature	Title	Date
and, MSH BioPharma, Inc.		
Name of surviving entity	President	7/12/13

8) Signatures - Must be signed by: An officer of each Nevada corporation; All general partners of

* The articles of merger must be signed by each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this page or as an attachment, as needed.

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate tees.

Nevada Secretary of State 92A Merger Page 6 Revised: 8-31-11

AGREEMENT AND PLAN OF MERGER OF MSH PHARMA, INC. AND MSH BIOPHARMA, INC.

THIS AGREEMENT AND PLAN OF MERGER (the "Agreement") is made and entered into as of the 12 day of July, 2013, by and between MSH Pharma, Inc. ("MPI"), a corporation organized and existing under the laws of the State of California (MPI being hereinafter sometimes referred to as the "Merging Corporation") and MSH BioPharma, Inc. ("MSH"), a corporation organized and existing under the laws of the State of Nevada (MSH being hereinafter sometimes referred to as the "Surviving Corporation"), said two corporations being hereinafter sometimes referred to collectively as the "Constituent Corporations";

WHEREAS, the Board of Directors and Shareholders of each of the Constituent Corporations deem it advisable and in the best interests of the Constituent Corporations that MPI be merged with and into MSH, with MSH being the Surviving Corporation, under and pursuant to the laws of the State of Nevada and on the terms and conditions set forth herein;

NOW THEREFORE, the parties hereto agree as follows:

ARTICLE I MERGER

- 1.1 MPI shall be merged with and into MSH in accordance with the laws of the States of California and Nevada. The separate corporate existence of MPI shall thereby cease, and MSH shall be the Surviving Corporation. It is the intent of the parties that the merger described herein qualify as a merger as defined by Section 368(a)(1)(A) of the Internal Revenue Code of 1986, as amended (the "Code") so that any shares of MSH common stock received by the shareholders of MPI, shall be received income tax-free under Code Section 354 and the Treasury Regulations issued thereunder.
- 1.2 The name which the Surviving Corporation is to have after the merger shall be "MSH BioPharma, Inc."
- 1.3 On the Closing Date (as defined in Section 2.1 below), the separate existence of the Merging Corporation shall cease. Except as herein otherwise specifically set forth, from and after the Closing Date the Surviving Corporation shall possess all of the rights, privileges, immunities and franchises, to the extent consistent with its Articles of Incorporation, of the Constituent Corporations. All the rights, privileges, powers and franchises of the Merging Corporation, of a public as well as of a private nature, and all property, real, personal and mixed of the Merging Corporation, and all debts due on whatever account to it, including all choses in action and all and every other interest of or belonging to it, shall be taken by and deemed to be transferred to and vested in the Surviving Corporation without further act or deed; and all such property, rights, privileges, immunities and franchises, of a public as well as of a private nature, and all and every other interest of the Merging Corporation shall be thereafter as effectually the property of the Surviving Corporation as they were of the Merging Corporation.

1.4 From and after the Closing Date, the Surviving Corporation shall be subject to all the duties and liabilities of a corporation organized under the Nevada Business Corporation Act and shall be liable and responsible for all the liabilities and obligations of the Constituent Corporations. The rights of the creditors of the Constituent Corporations, or of any person dealing with such corporations, or any liens upon the property of such corporations, shall not be impaired by this merger, and any claim existing or action or proceeding pending by or against either of such corporations may be prosecuted to judgment as if this merger had not taken place, or the Surviving Corporation may be proceeded against or substituted in place of the Merging Corporation. Except as otherwise specifically provided to the contrary herein, the identity, existence, purposes, powers, franchises, rights immunities and liabilities of the Surviving Corporation shall continue unaffected and unimpaired by the merger.

ARTICLE II TERMS AND CONDITIONS OF THE MERGER

The terms and conditions of the merger shall be as follows:

- 2.1 The merger shall become effective upon such date as Articles of Merger are filed in the State of Nevada, pursuant to Nevada Revised Statutes 92.A Section 100 et seq. The date of such effectiveness is referred to in this Agreement as the "Closing Date."
- 2.2 Prior to the Closing Date, the Constituent Corporations shall take all such action as shall be necessary or appropriate in order to effect the merger. If at any time after the Closing Date, the Surviving Corporation shall determine that any further conveyance, assignment or other documents or any further action is necessary or desirable in order to vest in, or confirm to, the Surviving Corporation full title to all of the property, assets, rights, privileges and franchises of the Constituent Corporations, or either of them, the officers and directors of the Constituent Corporations shall execute and deliver all such instruments and take all such further actions as the Surviving Corporation may determine to be necessary or desirable in order to vest in and confirm to the Surviving Corporation title to and possession of all such property, assets, rights, privileges, immunities and franchises, and otherwise to carry out the purposes of this Agreement and Plan.

ARTICLE III CHARTER AND BYLAWS; DIRECTORS AND OFFICERS

3.1 The Articles of Incorporation of MSH, as in effect immediately prior to the Closing Date, shall, after the merger, continue to be the Articles of Incorporation of the Surviving Corporation until duly amended in accordance with law, and no change to such Articles of Incorporation shall be effected by the merger.

- 3.2 The Bylaws of MSH, as in effect immediately prior to the Closing Date, shall, after the merger, continue to be the Bylaws of the Surviving Corporation until duly amended in accordance with law, and no change to such Bylaws shall be effected by the merger.
- 3.3 The persons who are the Directors and officers of MSH immediately prior to the Closing Date shall, after the merger, continue as the Directors and officers of the Surviving Corporation without change, to serve, subject to the provisions of the Bylaws of the Surviving Corporation, until their successors have been duly elected and qualified in accordance with the laws of the State of Nevada and the Articles of Incorporation and Bylaws of the Surviving Corporation.

ARTICLE IV CONVERSION OF SHARES

- 4.1 The Surviving Corporation presently has approximately 2,875,000 shares of \$.001 par value common stock ("MSH Common") issued and outstanding, which shares of MSH Common are the only outstanding shares of the Surviving Corporation.
- 4.2 The Merging Corporation presently has approximately 1000 shares of no par value common stock ("MPI Common") issued and outstanding which is owned by the Shareholders of the Merging Corporation.
- 4.3 At the Closing Date, each issued and outstanding share of MPI Common shall be converted into one thousand five hundred (1500) shares of MSH Common.

ARTICLE V MISCELLANEOUS

- 5.1 This Agreement constitutes the complete and exclusive agreement of the parties regarding the subject matter of this Agreement. No representation, statement, condition or warranty not contained in this Agreement shall be binding on Parties or have any force or effect whatsoever.
- 5.2 This Agreement shall be binding on, and inure to the benefit of, the Parties and their respective heirs, personal and legal representatives, executors, administrators, successors and assigns.
- 5.3 All headings herein are inserted only for convenience and ease of reference and are not to be considered in the construction or interpretation of any provision of this Agreement. All references in this Agreement to "Section" are references to the Sections of this Agreement unless the context clearly indicates to the contrary.
- 5.4 Should any provision of this Agreement be held to be void and unenforceable, the remaining provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions were deleted. If any term of this Agreement is held to be overly broad or unacceptable in scope or duration, such term shall be adjusted as minimally as necessary so as to be legally acceptable and shall be construed as originally so drafted.
- 5.5 The parties agree that irreparable damage will result if this Agreement is not performed in accordance with its terms, and the Parties agree that any damages available at law for a breach of

this Agreement would not be an adequate remedy. Therefore, the provisions hereof and the obligations of the Parties hereunder shall be enforceable in a court of equity, or other tribunal with jurisdiction, by a decree of specific performance, and appropriate injunctive relief may be applied for an granted in connection therewith. Such remedies and all other remedies provided for in this Agreement shall, however, be cumulative and not exclusive and shall be in addition to any other remedies that a Party may have under this Agreement, at law or in equity. The remedies under this Agreement are cumulative and shall not exclude any other remedies to which any person may be lawfully entitled.

- 5.6 Each Party agrees to execute and deliver such additional documents and instruments and to perform such additional acts as may be necessary or appropriate to effectuate, carry out and perform all of the terms, provisions, and conditions of this Agreement and the transactions contemplated hereby.
- 5.7 This Agreement may be executed in any number of counterparts with the same effect as if all signatories had signed the same document. All counterparts shall be construed together and constitute the same instrument.
- In the event that any dispute between the Parties should result in litigation or arbitration, the prevailing party(ies) in such dispute shall recover from the non-prevailing party(ies) all reasonable fees, costs and expenses of enforcing any right of the prevailing party, including without limitation, reasonable attorneys' fees and expenses, all of which shall be deemed to have accrued upon the commencement of such action and shall be paid whether or not such action is prosecuted to judgment. Any judgment or order entered in such action shall contain a specific provision providing for the recovery of attorney fees and costs incurred in enforcing such judgment and an award of prejudgment interest from the date of the breach at the maximum rate of interest allowed by law. For the purposes of this Section: (a) attorneys' fees shall include, without limitation, fees incurred in the following: (1) postjudgment motions; (2) contempt proceedings; (3) garnishment, levy, and debtor and third party examinations; (4) discovery; and (5) bankruptcy litigation and (b) prevailing party shall mean the party who is determined in the proceeding to have prevailed or who prevails by dismissal, default or otherwise.
- 5.9 This Agreement shall be construed under the laws of the State of Nevada applicable to contracts wholly made and to be wholly performed in such State. Any disputes regarding this Agreement or the parties' rights and obligations under this Agreement will be submitted to binding arbitration before a single arbitrator selected in accordance with the rules of Commercial Arbitration of the American Arbitration Association ("AAA") and conducted in accordance with the AAA's rules of Commercial Arbitration as modified by this Section 5.9 and applying Nevada law. The arbitration proceedings shall be conducted in Las Vegas, Nevada. The arbitrator shall be an attorney at law licensed by the State of Nevada. The arbitrator rendering judgment upon disputes between parties shall, after reaching a decision, prepare and distribute to the parties a writing describing the findings of fact and conclusions of law relevant to such decision and any award and setting forth the reasons for the giving or denial of any requested relief. If neither party files a notice of appeal within 10 days of the decision being issued by the Arbitrator, the decision and any award made by the arbitrator shall be final and binding and not subject to

judicial review. Any judgment may be entered by any state district court of Las Vegas, Nevada, or by any other court having jurisdiction over the parties.

IN WITNESS WHEREOF, this Agreement and Plan has been signed by the duly authorized officers of the Constituent Corporations pursuant to the authorization by the Board of Directors and Shareholders of the Constituent Corporations, all as of the day and year first above written.

MPI:

MSH Pharma, Inc.

James Lipton, President

ATTEST:

Lubna Lipton, Secretary

MSH:

MSH BIOPHARMA, INC.

Rebecca Dubowy Posten, President

ATTEST:

Matthew Lipton, Secretary

PATENT REEL: 031411 FRAME: 0378

RECORDED: 10/15/2013